Successful salvage treatment of Scedosporium apiospermum keratitis with topical voriconazole after failure of natamycin

Annals of Pharmacotherapy

Volumn 43, Issue 6, 2009, Pages 1139-1142

  Al Badriyeh, Daoud ^a   Leung, Lok ^b   Davies, Geoffrey E ^c   Stewart, Kay ^a   Kong, David ^a  

^a MONASH UNIVERSITY   (Australia)

^b ROYAL VICTORIAN EYE AND EAR HOSPITAL   (Australia)

^c Land Systems Division   (Australia)

Author keywords

Keratitis; Scedosporium apiospermum; Topical voriconazole

Indexed keywords

CHLORAMPHENICOL; NATAMYCIN; VORICONAZOLE;

ADULT; ANAMNESIS; ANTERIOR EYE CHAMBER; ARTICLE; CASE REPORT; CORNEA EDEMA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EPITHELIZATION; EYE EXAMINATION; EYE PAIN; FEMALE; FUNGAL DETECTION; FUNGUS CULTURE; HUMAN; INTRAOCULAR PRESSURE; KERATOMYCOSIS; MONOTHERAPY; PATHOGENESIS; PRIORITY JOURNAL; RECURRENT INFECTION; SCEDOSPORIUM APIOSPERMUM; SLIT LAMP; VISUAL ACUITY;

ADMINISTRATION, TOPICAL; ANTIFUNGAL AGENTS; COST-BENEFIT ANALYSIS; EYE INFECTIONS, FUNGAL; FEMALE; HUMANS; KERATITIS; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NATAMYCIN; PYRIMIDINES; RECURRENCE; SALVAGE THERAPY; SCEDOSPORIUM; TRIAZOLES; VISUAL ACUITY;

EID: 67249105345     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1M008     Document Type: Article

References (12)

1. Ozbek Z, Kang S, Sivalingam J, Rapuano CJ, Cohen EJ, Hammersmith KM. Voriconazole in the management of Alternaria keratitis. Cornea 2005;25:242-244
2. Wu Z, Ying H, Yiu S, Irvine J, Smith R. Fungal keratitis caused by Scedosporium apiospermum. Cornea 2002;21:519-523
3. Cortez KJ, Roilides E, Quiroz-Telles F, et al. Infections caused by Scedosporium spp. Clin Microbiol Rev 2008;21:157-197
4. Hariprasad SM, Mieler WF, Lin TK, Sponsel WE, Graybill JR. Voriconazole in the treatment of fungal eye infections: a review of current literature. Br J Ophthalmol 2008;92:871-878 (Pubitemid 351969658)
5. Keay L, Edwards K, Naduvilath T, et al. Microbial keratitis: predisposing factors and morbidity. Ophthalmology 2006;113:109-116 (Pubitemid 43021736)
6. Parfitt K. Natamycin monograph. Martindale: the complete drug reference. 32nd ed. London: Pharmaceutical Press, 2009.
7. Shah KB, Wu TG, Wilhelmus KR, et al. Activity of voriconazole against corneal isolates of Scedosporium apiospermum. Cornea 2003;22:33-36
8. Ozturk F, Yavas GF, Kusbeci T, et al. Efficacy of topical caspofungin in experimental Fusarium keratitis. Cornea 2007;26:726-728 (Pubitemid 47080294)
9. Lau D, Ferdinands M, Leung L, et al. Penetration of voriconazole 1% eyedrops into human aqueous humor. A prospective open label study. Arch Ophthalmol 2008;126:343-346
10. Hernandez PC, Linares TF, Burgos SJA, et al. Voriconazole in fungal keratitis caused by Scedosporium apiospermum. Ann Pharmacother 2004;38:414-417 Epub 30 Jan 2004. DOI 10.1345/aph.1D128.
11. Al-Badriyeh D, Li J, Leung L, et al. Stability of voriconazole eye drops for off-label use in the management of ophthalmic fungal infections. Am J Health Syst Pharm (in press).
12. Product information. Vfend (voriconazole). New York: Pfizer, March 2008.